Viatris commences tender offer to acquire Pacira BioSciences
PCRX•Viatris has commenced a tender offer to acquire Pacira BioSciences for $36.50 per share in cash. Pacira would become a wholly owned Viatris subsidiary, and its board unanimously recommends that shareholders accept the offer and tender their shares.
1. Tender offer details
Viatris said it has commenced a tender offer to acquire Pacira BioSciences for $36.50 per share in cash. Pacira would become a wholly owned subsidiary of Viatris after the merger. Pacira’s board unanimously recommends that shareholders accept the offer and tender their shares; the offer is not subject to a financing condition.
